logo
Edison will pay U.S. a record $82.5 million in Bobcat fire settlement

Edison will pay U.S. a record $82.5 million in Bobcat fire settlement

Yahoo23-05-2025

Southern California Edison has agreed to pay $82.5 million to cover costs and damages from the 2020 Bobcat fire in what federal officials are calling a record settlement for one of the largest blazes in Los Angeles County.
Federal officials allege that the Bobcat fire, which burned more than 114,000 acres in 2020, ignited when trees that were not properly maintained by Southern California Edison and its tree maintenance contractor came into contact with power lines.
Edison agreed to pay the settlement within 60 days of the effective date of the agreement, which was May 14, without admitting wrongdoing or fault.
The utility did not immediately respond to a request for comment Friday.
The U.S. attorney's office in Los Angeles called it "the largest-ever wildfire cost recovery settlement" by the government in the Central District of California.
'This record settlement against Southern California Edison provides meaningful compensation to taxpayers for the extensive costs of fighting the Bobcat Fire and for the widespread damage to public lands,' U.S. Atty. Bill Essayli said in a news release. 'My office will continue to aggressively pursue recovery for suppression costs and environmental damages from any entity that causes harm to the public's forests and other precious national resources."
The settlement comes as Edison seeks to raise customer rates by 10% in order to pay for wildfire mitigation and cover 'reasonable costs of its operations, facilities [and] infrastructure," according to the utility giant's request filing. It also comes just months after fire ravaged Pacific Palisades and Altadena.
The California Public Utilities Commission is expected to make a decision this summer on the request. If approved, the rate hike would mean an $18 average increase in monthly electrical bills for Edison's 15 million customers.
Read more: Edison's proposed rate hike angers L.A. wildfire survivors
The federal government filed a lawsuit in September 2023 on behalf of the Forest Service against Edison and Utility Tree Service seeking damages in excess of $121 million for the cost of extinguishing the Bobcat fire and the resulting damage to property and natural resources.
The fire, which began on Sept. 6, 2020, destroyed 87 homes, 83 other structures and 178 vehicles. An additional 28 homes were also damaged and at least six firefighters were injured while battling the fire.
Federal officials said it also resulted in years of closure of more than 100 miles of trails and numerous campgrounds and had a harmful impact on habitats and wildlife, including to the "federally endangered wildlife-mountain yellow-legged frog, federally threatened fish and birds and irreplaceable cultural and heritage resources."
'These settlements are essential in restoring our landscapes after wildfires," acting U.S. Forest Service Pacific Southwest Regional Forester Jason Kuiken said in the news release.
Tony Martinez, deputy forest supervisor for the Angeles National Forest, said the resources would "help rehabilitate burned areas, restore wildlife habitats, and strengthen our forests' resilience to future wildfires."
Edison's safety record declined last year, with the number of fires sparked by its equipment soaring to 178, from 90 the year before and 39% above the five-year average.
In April, the chief executive of Southern California Edison's parent company said that the company was likely to suffer 'material losses' related to the deadly Eaton fire, which ignited on Jan. 7 and burned more than 14,000 acres in and around Altadena.
Investigations into the cause of the fire are continuing and have not concluded that Edison's equipment sparked the blaze, Edison International Chief Executive Pedro Pizarro said during the company's first-quarter earnings call in April.
Edison has previously acknowledged that it could be responsible for the blaze and said this month that a dormant power line might have been the cause.
The Eaton fire killed 18 people and destroyed thousands of homes and other structures. Early estimates put the cost of damage at $10 billion, but experts said that number would grow.
Times staff writer Caroline Petrow-Cohen contributed to this report.
Sign up for Essential California for news, features and recommendations from the L.A. Times and beyond in your inbox six days a week.
This story originally appeared in Los Angeles Times.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

HistoSonics completes pivotal histotripsy system trial enrolment
HistoSonics completes pivotal histotripsy system trial enrolment

Yahoo

time13 hours ago

  • Yahoo

HistoSonics completes pivotal histotripsy system trial enrolment

As reports of an acquisition by one of the leading players in the medical device space percolate, HistoSonics has completed enrolment in a pivotal trial to evaluate its histotripsy platform in treating kidney tumours. The US company's prospective, multi-centre, single-arm pivotal #HOPE4KIDNEY (NCT05820087) trial is designed to evaluate the effectiveness and safety of the Edison system for the destruction of kidney tissue by treating primary solid renal tumours. A total of 67 patients have been enrolled with a single, non-metastatic solid kidney mass ≤3cm. Patients will be treated with the Edison system and followed for five years post-procedure, with data at the 90-day evaluation point to be submitted in support of regulatory approval with the US Food and Drug Administration (FDA). The Edison system uses a technology called histotripsy, involving the delivery of non-thermal, non-invasive focused ultrasound waves to target and eliminate cancerous liver tissue. The system received de novo clearance from the US Food and Drug Administration (FDA) in 2023 and last month secured its first major insurance coverage from a new healthcare policy from Healthcare payor Blue Cross Blue Shield of Michigan (BCBSM) and health plan option Blue Care Network. HistoSonics' vision is for its Edison system to become a 'foundational, non-invasive' solution across a range of clinical applications, the company's CEO, Mike Blue stated. 'Completing enrolment in our pivotal kidney tumour trial represents a significant milestone toward that goal and reinforces our confidence in expanding histotripsy into additional tumour types and indications,' said Blue. In May, Edison histotripsy system has been granted controlled early limited market access in the UK under an Unmet Clinical Need Authorisation (UCNA) under the UK's Innovative Devices Access Pathway (IDAP), launched by the UK Government in 2023 to help fast-track 'transformative medical technologies' into the healthcare system. As first reported by the Financial Times last month, HistoSonics is seeking a valuation of more than $2.5bn for a takeover of the company, with Medtronic, GE HealthCare and Johnson & Johnson (J&J), a longtime backer of HistoSonics, among the interested parties evaluating the business. J&J most recently participated in HistoSonics' $102m Series D funding round. "HistoSonics completes pivotal histotripsy system trial enrolment" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Musk Is a Genius, but He Isn't a Political One
Musk Is a Genius, but He Isn't a Political One

Wall Street Journal

time16 hours ago

  • Wall Street Journal

Musk Is a Genius, but He Isn't a Political One

Seeing Elon Musk collide with President Trump was like watching an architect argue with a hurricane. Mr. Musk's engineering intellect has reshaped entire industries yet proved startlingly insufficient in navigating political alliances and public sentiment. Through history, titans of industry and technology have collided with the messy realities of politics only to find their precision-driven minds flummoxed by the fuzzy logic of public opinion, coalitions and compromise. Thomas Edison, Henry Ford, and even Steve Jobs each in his time learned that politics doesn't obey the laws of physics.

HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors
HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors

Yahoo

time19 hours ago

  • Yahoo

HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors

Pivotal Study Advances to Establish Histotripsy as a Non-Thermal, Surgery-Free Alternative to Destroy and Liquefy Kidney Tumors MINNEAPOLIS, June 06, 2025--(BUSINESS WIRE)--HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient enrollment in its pivotal #HOPE4KIDNEY trial. This prospective, multi-center, single-arm trial is designed to evaluate the safety and effectiveness of the Edison System in destroying kidney tissue by treating primary solid kidney tumors. The trial enrolled patients with a single, non-metastatic solid kidney mass ≤3 cm, confirmed by imaging and biopsy. Subjects will be followed for five years post-procedure, with evaluations at multiple time points, including 14-day, 30-day, 90-day, 180-day, and annual assessments. The Edison System remains in investigational use for kidney applications and is not yet FDA-approved for this indication. Data from the #HOPE4KIDNEY trial is expected to support a future submission for regulatory clearance to expand the use of histotripsy to treat kidney tissue/tumors. The Edison System is the first and only platform to use histotripsy, a non-thermal, non-invasive focused ultrasound technology, to mechanically liquefy tumors without surgery, radiation, or systemic therapies. Unlike invasive surgical approaches, histotripsy does not require incisions and enables real-time imaging and treatment monitoring, allowing physicians to target and control tissue destruction while sparing surrounding structures. "Our vision is for the Edison System to become a foundational, non-invasive solution across a wide range of clinical applications," said Mike Blue, President and CEO, HistoSonics. "Completing enrollment in our pivotal kidney tumor trial represents a significant milestone toward that goal and reinforces our confidence in expanding histotripsy into additional tumor types and indications. This achievement reflects the dedication of our team and clinical partners and brings us closer to transforming the treatment of solid tumors without the need for surgery." Dr. William C. Huang, MD FACS, Professor and Vice Chair of Urology at the NYU Grossman School of Medicine serves as a principal investigator at the NYU Langone Medical Center, the top enrolling site in the trial. Dr. Huang commented, "Histotripsy offers a novel, completely non-invasive treatment paradigm for kidney tumors that precisely images and treats tumors while preserving surrounding critical structures thereby minimizing the morbidity associated with traditional surgical and thermal ablative techniques." Dr. Michael McDonald, Assistant Professor of Urology at the University of Central Florida College of Medicine and Urologic Surgeon at AdventHealth at Celebration Florida, serves as a principal investigator for one of the participating sites in the trial. Dr. McDonald commented, "HistoSonics represents a paradigm shift proving that the most profound treatments for both benign and malignant diseases need not be the most invasive. The ability to precisely target and destroy tumors without scalpel or scar is the next step in the evolution of non-surgical intervention." The Edison System has not been evaluated for the treatment of any specific disease, including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumour progression, 5-year survival or overall survival). United States Intended Use Statement: The Edison System is intended for the non-invasive mechanical destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors via histotripsy. The FDA has not evaluated the Edison System for the treatment of any disease including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumor progression, 5-year survival or overall survival). The System should only be used by physicians who have completed training performed by HistoSonics, and its use guided by the clinical judgment of an appropriately trained physician. Refer to the device Instructions for Use for a complete list of warnings, precautions, and a summary of clinical trial results, including reported adverse events. About HistoSonics HistoSonics is a privately held medical device company developing a non-invasive platform and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquify unwanted tissue and tumors. The company is currently focused on commercializing their Edison System in the US and select global markets for liver treatment while expanding histotripsy applications into other organs like kidney, pancreas, prostate, and others. HistoSonics has offices in Ann Arbor, Michigan and Minneapolis, MN. For more information on the Edison Histotripsy System please visit: For patient-related information please visit: View source version on Contacts Media contacts:Josh KingVice President of 608.332.8124 Kimberly HaKKH Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store